Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH.

Cell death and differentiation - 1 Jul 2020

Tan Mingjun, Mosaoa Rami, Graham Garrett T, Kasprzyk-Pawelec Anna, Gadre Shreyas, Parasido Erika, Catalina-Rodriguez Olga, Foley Patricia, Giaccone Giuseppe, Cheema Amrita, Kallakury Bhaskar, Albanese Chris, Yi Chunling, Avantaggiati Maria Laura

Abstract excerpt

Nonalcoholic fatty liver disease (NAFLD) and its evolution to inflammatory steatohepatitis (NASH) are the most common causes of chronic liver damage and transplantation that are reaching epidemic proportions due to the upraising incidence of metabolic syndrome, obesity, and diabetes. Currently, there is no approved treatment for NASH. The mitochondrial citrate carrier, Slc25a1, has been proposed to play an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetyl Coenzyme A
Share to Citric Acid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diet, High-Fat

Share to Gluconeogenesis

Share to Glucose Intolerance

Share to Hepatomegaly

Share to Hyperglycemia

Share to Lipogenesis

Source

Open in PubMed Open full text

Identifiers

PMID: 31959914
DOI: 10.1038/s41418-020-0491-6
PMCID: PMC7308387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH.PMID 31959914Read ↗

Advances into Understanding the Vital Role of the Mitochondrial Citrate Carrier (CIC) in Metabolic Diseases.Semantic proximity Read ↗

Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial functionSemantic proximity Read ↗

Oncogenic KRASG12D Reprograms Lipid Metabolism by Upregulating SLC25A1 to Drive Pancreatic TumorigenesisSemantic proximity Read ↗

The citrate transporters SLC13A5 and SLC25A1 elicit different metabolic responses and phenotypes in the mouse.Semantic proximity Read ↗

Altered drug metabolism and increased susceptibility to fatty liver disease in myotonic dystrophySemantic proximity Read ↗

SLC13A2-transported citrate is a metabolic signal for PKM2 acetylation and degradation to suppress tumor growthSemantic proximity Read ↗

Liver Pyruvate Kinase Promotes NAFLD/NASH in Both Mice and Humans in a Sex-Specific Manner.Semantic proximity Read ↗

A liver-specific mitochondrial carrier that controls gluconeogenesis and energy expenditureSemantic proximity Read ↗

Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease.Semantic proximity Read ↗

Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways.Semantic proximity Read ↗

Elimination of FKBP51 attenuates CCl4-induced liver injury via enhancement of mitochondrial function by increased Parkin activitySemantic proximity Read ↗

High-throughput screening identifies small molecule inhibitors of thioesterase superfamily member 1: Implications for the management of non-alcoholic fatty liver diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.